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Abstract
Background: Long noncoding RNAs (lncRNAs) have emerged as important regulators of tumorigenesis and cancer
progression. Recently, the lncRNA AGAP2-AS1 was identified as an oncogenic lncRNA in human non-small cell lung
cancer (NSCLC) and its elevated expression was linked to NSCLC development and progression. However, the
expression pattern and molecular mechanism of AGAP2-AS1 in gastric cancer (GC) have not been characterized.
Methods: Bioinformatic analysis was performed to determine AGAP2-AS1 expression levels in the GC and normal
tissues using gene profiling data from the Gene Expression Omnibus. Quantitative real-time polymerase chain
reaction was used to validate AGAP2-AS1 expression in the GC tissues/cell lines compared with that in the adjacent
nontumorous tissues/normal epithelial cells. Loss- and gain-of-function approaches were performed to investigate
the effect of AGAP2-AS1 on GC cell phenotypes. The effect of AGAP2-AS1 on cell proliferation was evaluated by
MTT, colony formation, flow cytometry, and in vivo tumor formation assays. The effects of AGAP2-AS1 on cell
migration and invasion were examined using Transwell assays. Chromatin immunoprecipitation, luciferase reporter
assays, RNA pull-down, and RNA immunoprecipitation were used to investigate the factors involved in AGAP2-AS1
dysregulation and the mechanism of action of AGAP2-AS1 in the GC cells.
Results: AGAP2-AS1 was highly expressed in the GC tissues and cell lines, and patients with higher AGAP2-AS1
expression had a poorer prognosis and shorter overall survival. Furthermore, knockdown of AGAP2-AS1 significantly
inhibited GC cell proliferation, migration, and invasion in vitro and tumor growth in vivo. AGAP2-AS1 overexpression
promoted cell growth and invasion. In addition, the transcription factor SP1 activated AGAP2-AS1 expression in the GC
cells. AGAP2-AS1 functions as an oncogenic lncRNA by interacting with LSD1 and EZH2 and suppressing CDKN1A (P21)
and E-cadherin transcription.
Conclusions: Taken together, these findings imply that AGAP2-AS1 upregulated by SP1 plays an important role in GC
development and progression by suppressing P21 and E-cadherin, which suggests that AGAP2-AS1 is a potential
diagnostic marker and therapeutic target for GC patients.
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Background
Gastric cancer (GC) is still one of the most common
malignancies, and one of the leading causes of cancer-
related death worldwide [1, 2]. Although numerous efforts
have been made to improve the diagnosis and survival of
GC patients, this disease remains a major challenge due to
the limited therapeutic options, tumor metastasis, and re-
currence [3]. Despite advances in our understanding of
the pathology of GC and the improvement of individu-
alized treatment, the 5-year overall survival (OS) rate of
GC patients is still lower than 30% due to more than
half of patients already being at a progressive stage
when diagnosed [4, 5]. It is thus essential to identify
new regulators involved in GC, and there is an urgent
need to develop novel diagnostic markers and effective
therapeutic targets for GC patients.
In recent years, the improvement of RNA sequencing
techniques and bioinformatics methods has led to the
sequencing of the human genome and the ENCODE
project [6]. As a result, the GENCODE annotation re-
vealed that less than 3% of the human genome consists
of protein-coding genes, while the majority of the rest
transcribes into noncoding transcripts [7]. Increasing
evidence has revealed that these noncoding RNAs such
as miRNAs play critical roles in human cancer develop-
ment [8]. Long noncoding RNAs (lncRNAs) are newly
identified members of the noncoding RNA family,
which are greater than 200 nucleotides (nt) in length
and lack protein-coding ability [9]. It has been docu-
mented that lncRNAs participate in diverse biological
processes, including X-chromosome imprinting, chro-
matin remodeling, RNA alternative splicing and decay,
cell differentiation, cell fate control, cancer cell metas-
tasis, and drug resistance [10]. Notably, numerous
studies have linked lncRNA dysregulation with human
diseases, especially cancer [11]. lncRNAs have thus
been highlighted as critical regulators of tumorigenesis
and cancer progression, and numerous lncRNAs have
been found to function as oncogenes, tumor suppres-
sors, or both depending on the circumstances [12].
Recently, several GC-associated lncRNAs have been
characterized, and their biological function and underlying
mechanisms have been documented, such as ZFAS1 [13],
HOTAIR [14], HOXA-AS2 [15], and MEG3 [16]. In
addition, the overexpression of LINC00152 was shown to
promote GC cell proliferation and accelerate cell cycle
progression by interacting with EZH2 and thereby
suppressing the transcription of CDKN2B and P21 [17].
Another lncRNA termed BC032469 was also shown to be
upregulated in the GC tissues and to function as com-
peting endogenous RNA (ceRNA) to antagonize the
miR-1207-5p suppression of hTERT, which promotes
cell growth [18]. Moreover, low expression of the
lncRNA LINC00261 was shown to be associated with a
poor prognosis of GC patients, and overexpressed
LINC00261 was found to suppress GC cell metastasis
by affecting the epithelial–mesenchymal transition [19].
Although several lncRNAs with oncogenic or cancer-
suppressive functions have been identified in GC, it re-
mains unclear whether other lncRNAs are also involved
in GC tumorigenesis and progression. Therefore, it is
critically important to investigate other GC-associated
lncRNAs and elucidate their biological consequences in
order to understand the pathogenesis of GC.
AGAP2-AS1, an antisense lncRNA transcribed from a
gene located at 12q14.1, which is 1567 nt in length, has
been found to be overexpressed in human non-small cell
lung cancer (NSCLC). A recent study showed that in-
creased AGAP2-AS1 promotes cell proliferation in NSCLC
by suppressing the transcription of its targets KLF2 and
LATS2 [20]. However, the expression pattern, biological
function, and underlying mechanism of AGAP2-AS1 in
human GC remain unclear. In this study, we identified that
AGAP2-AS1 was highly expressed in the GC tissues and
cells and that higher AGAP2-AS1 expression was related
to poor patient prognosis. We also investigated the
contributions of AGAP2-AS1 to GC tumorigenesis and
progression by applying loss- or gain-of-function as-
says. Moreover, we used RNA immunoprecipitation
(RIP), chromatin immunoprecipitation (ChIP), and lucife-
rase reporter assays to investigate the factors involved in
AGAP2-AS1 dysregulation and characterize the mech-
anism by which AGAP2-AS1 regulates its targets in the
GC cells. Taken together, the obtained findings may
provide new insights into the critical role of the lncRNA
AGAP2-AS1 in human GC tumorigenesis and progression.
Methods
Tissue samples and cell lines
Fifty paired GC and adjacent nontumor tissue samples
were obtained from patients who had been diagnosed
with GC based on a histopathological evaluation and
undergone surgery at the Second Affiliated Hospital of
Nanjing Medical University between 2011 and 2012.
Clinicopathological characteristics, including gender,
age, tumor-node-metastasis (TNM) staging, and tumor
size, were recorded. These patients had not undergone
any local or systemic treatment before surgery. All tissue
samples were immediately snap-frozen in liquid nitrogen
and stored at −80 °C until used for RNA extraction. This
study was approved by the Research Ethics Committee
of Nanjing Medical University, China. Written informed
consent was obtained from all patients. Five GC cell
lines (BGC823, SGC7901, AGS, MGC803, and MKN45)
and one normal gastric epithelial cell line (GES1) were
purchased from the Shanghai Cell Bank of the Chinese
Academy of Sciences (Shanghai, China). The BGC823,
MGC803, and MKN45 cells were cultured in RPMI
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1640; the SGC7901 and AGS cells were cultured in
DMEM (GIBCO-BRL) supplemented with 10% fetal bo-
vine serum (FBS), 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 °C
in 5% CO2.
RNA extraction and qRT-PCR assays
The total RNA of the tissue samples and cells was isolated
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), in
accordance with manufacturer’s instructions. Then, 1 μg
of total RNA was reverse-transcribed in a volume of 20 μl
using random and oligo dT primers under standard con-
ditions, in accordance with the instructions of the Prime-
Script RT Kit (TaKaRa, Dalian, China). For qRT-PCR
assays, we used SYBR Premix Ex Taq (TaKaRa, Dalian,
China) to determine the expression levels of AGAP2-AS1
and its targets, in accordance with manufacturer’s instruc-
tions. The expression data of AGAP2-AS1 were normal-
ized to the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The primer sequences are listed
in Additional file 1: Table S1.
Cell transfection
The human AGAP2-AS1 cDNA sequence was synthesized
and then ligated into the pCDNA3.1 vector (Invitrogen,
Shanghai, China). AGAP2-AS1 stealth siRNAs were pur-
chased from Invitrogen, and AGAP2-AS1 short hairpin
RNA oligos were synthesized, annealed, and ligated into
the shRNA vector. Plasmid vectors (pCDNA-AGAP2-
AS1, sh-AGAP2-AS1, and empty vector) for transfection
were prepared using Midiprep kits (Qiagen, Hilden,
Germany). si-AGAP2-AS1 or si-NC was transfected into
the BGC823 or AGS cells growing on six-well plates using
RNAiMAX (Invitrogen, Shanghai, China), in accordance
with manufacturer’s instructions. The siRNA and shRNA
sequences are listed in Additional file 1: Table S1. Forty-
eight hours after transfection, the cells were harvested for
qRT-PCR or Western blot analysis. The BGC823 cells sta-
bly transfected with sh-AGAP2-AS1 or empty vector were
selected by G418, and then the cloned cells were collected
for an in vivo tumorigenesis experiment.
Cell proliferation assays
The viability of the BGC823 and AGS cells after si-
AGAP2-AS1 (3000 cells/well) or negative control treat-
ment when grown on 96-well plates was monitored
using Cell Proliferation Reagent Kit I (MTT) (Roche
Applied Science) and EdU assay kit (Life Technologies
Corporation, Carlsbad, CA, USA), following manufac-
turer’s protocol. For each treatment group, wells were
assessed in triplicate. For the colony formation assay, the
BGC823 and AGS cells transfected with sh-AGAP2-AS1
or empty vector were cultured in six-well plates. After
2 weeks, the cells were fixed with methanol for 30 min.
After washing, the cells were stained with 0.5% crystal
violet for 30 min and counted. For cell cycle analysis,
the BGC823 and AGS cells transfected with si-AGAP2-
AS1 or negative control were harvested 48 h after trans-
fection by trypsinization. Then, these cells were stained
with propidium iodide (PI) using the CycleTEST™ PLUS
DNA Reagent Kit (BD Biosciences, Franklin Lakes, NJ,
USA), in accordance with manufacturer’s protocol, and
analyzed by FACScan. The proportions of the cells in
the G0/G1, S, and G2/M phases were counted. All experi-
ments were performed in quadruplicate.
Apoptosis assays
The BGC-823 and AGS cells transfected with si-AGAP2-
AS1 or si-NC were harvested 48 h after transfection by
trypsinization. After double staining with FITC-annexin V
and PI, the cells were analyzed with a flow cytometer
(FACScan®; BD Biosciences) equipped with CellQuest soft-
ware (BD Biosciences, Franklin Lakes, NJ, USA).
Cell migration and invasion assays
Twenty-four-well Transwell chambers with 8-μm pore
size polycarbonate (Corning Incorporated, Corning, NY,
USA) were used for cell migration and invasion assays.
For invasion assays, the top side of the membrane was
coated with Matrigel (BD Biosciences, Franklin Lakes,
NJ, USA), and then 1 × 105 cells (in each well) in serum-
free DMEM or RPMI 1640 medium were seeded on the
chambers. DMEM or RPMI 1640 containing 10% FBS
was added to the wells under the chamber. For migra-
tion analysis, 5 × 104 cells (in each well) in serum-free
DMEM or RPMI 1640 medium were seeded on the
chambers without Matrigel. After 24 h of incubation, cot-
ton swabs were used to remove the cells inside the upper
chamber, while the cells on the other side of the mem-
brane surface were fixed and stained with 0.5% crystal vio-
let solution. Five random fields were counted in each well.
Tumor formation assay
Four-week-old athymic BALB/c nude mice were main-
tained under specific pathogen-free conditions. The mice
were manipulated in accordance with the protocols ap-
proved by the Shanghai Medical Experimental Animal
Care Commission. The BGC823 cells stably transfected
with sh-AGAP2-AS1 or empty vector were harvested
and washed with PBS. Then, 1 × 107 cells were subcuta-
neously injected into the ventral side of each mouse for
tumor formation assays. The tumor volumes were exam-
ined every 3 days and calculated using the following equa-
tion: V = 0.5 × D × d2 (V, volume; D, longitudinal diameter;
and d, latitudinal diameter). This study was carried out in
strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved
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by the Committee on the Ethics of Animal Experiments of
Nanjing Medical University.
RNA immunoprecipitation (RIP)
RIP assay was used to determine whether AGAP2-AS1
interacts with or binds to RNA-binding proteins (EZH2,
SUZ12, and LSD1) in the human GC cells. The EZ-
Magna RIP kit (Millipore, Billerica, MA, USA) was used
to conduct the RIP experiment, following manufacturer’s
protocol. The BGC-823 and AGS cells were lysed using
complete RIP lysis buffer; then, the extract was incu-
bated with magnetic beads conjugated with EZH2,
SUZ12, and LSD1antibodies or control IgG (Millipore)
for 6–8 h at 4 °C. Next, the beads were washed with
washing buffer and incubated with proteinase K at 55 °C
for 30 min to remove the proteins. Finally, purified RNA
was reverse-transcribed into cDNA and subjected to
qRT-PCR analysis to determine the presence of AGAP2-
AS1 using specific primers. EZH2 (Cat.No.17-662),
SUZ12 (Cat.No.03-179), LSD1 (Cat.No.17-10531), CoREST
(Cat.No.07-455), and HuR (Cat.No.03-102) antibodies were
purchased from EMDMillipore.
Luciferase reporter assays
The JASPAR (http://jaspar.genereg.net/) online data-
base was used to predict potential transcription factor
binding sites at the AGAP2-AS1 promoter regions,
and several SP1 binding motifs were identified. The
AGAP2-AS1 promoter region (2000 bp) was then
synthesized and inserted into a pGL3-basic vector
(Promega, Madison, WI, USA). The successful integra-
tion of this sequence into the vector was verified by se-
quencing. The Dual-Luciferase Assay Kit was used to
assess luciferase activities, following manufacturer’s
protocol.
Chromatin immunoprecipitation (ChIP) assays
The EZ-Magna ChIP kit (EMD Millipore) was used to
conduct the ChIP assays. In accordance with manufac-
turer’s protocol, the BGC-823 and AGS cells were fixed
with 4% paraformaldehyde and incubated with glycine for
10 min to generate DNA–protein cross-links. Then, the
cells were lysed with Cell Lysis Buffer and Nuclear Lysis
Buffer and sonicated to generate chromatin fragments of
200–300 bp. Next, the lysates were immunoprecipitated
with Magnetic Protein A Beads conjugated with EZH2-
(Cat. 17-662, EMD Millipore), H3K27me3- (Cat. 17-622,
EMD Millipore), LSD1- (Cat. 17-1053, EMD Millipore),
or H3K4me2-specific antibodies (Cat. 17-677, EMD
Millipore), or IgG as a control. Finally, the precipitated
DNA was analyzed by qRT-PCR.
Fig. 1 AGAP2-AS1 is overexpressed in the human GC tissues and cells. a Data mining of AGAP2-AS1 expression levels in the GC tissue samples
from gene profiling (GSE51575 and GSE65801). b qRT-PCR analysis of AGAP2-AS1 level in the 50 paired GC tissues and adjacent nontumor tissues.
AGAP2-AS1 level was normalized to GAPDH expression. c qRT-PCR analysis of AGAP2-AS1 expression in the GC cell lines BGC823, MGC803, SGC7901,
AGS, and MKN45 and the normal gastric cell line GSE1. AGAP2-AS1 level was normalized to the GAPDH level. d GC patients were divided into two
groups according to AGAP2-AS1 expression profiles. The median fold change was used as the threshold. e Kaplan–Meier overall and disease-free
survival analyses were used to investigate the relationship between AGAP2-AS1 expression and GC patient survival. *P < 0.05, **P < 0.01
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Subcellular fractionation analysis
The distribution of AGAP2-AS1 in the nuclear and cyto-
solic fractions of the BGC823 and AGS cells was
assessed using the PARIS Kit (Life Technologies), in ac-
cordance with manufacturer’s instructions.
Western blot assays
RIPA extraction reagent (Beyotime, Beijing, China) sup-
plemented with protease inhibitor cocktail (Roche, CA,
USA) was used to lyse the BGC823 and AGS cells and
extract the protein. Then, 40 μg of protein was separated
by 8–12% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to 0.22-μm Pvdf membranes
(Millipore). The membranes were sealed using 5% BSA
in PBS and incubated with P21, E-cadherin, or GAPDH
antibodies (all from Cell Signaling Technology). ECL
chromogenic substrate was quantified by densitometry
(Quantity One software; Bio-Rad).
RNA pull-down assays
AGAP2-AS1 RNA was transcribed in vitro using T7
RNA polymerase, and pcDNA-AGAP2-AS1 vector was
used as template (Ambio Life). The transcribed RNA
was purified using the RNeasy Plus Mini Kit (Qiagen)
and treated with DNase I (Qiagen). The pull-down as-
says were performed using the Pierce™ Magnetic RNA-
Protein Pull-Down Kit (Thermo Fisher, Cat. 20164), in
accordance with manufacturer’s instructions. Purified
RNAs were biotin-labeled with the Pierce RNA 3′ End
Desthiobiotinylation Kit (Thermo Fisher, Cat. 20163).
Positive control, negative control, and biotinylated RNAs
were mixed and incubated with BGC823 cell lysates.
Then, magnetic beads were added to each binding reac-
tion and incubated at room temperature. Finally, the
beads were washed and the eluted proteins were de-
tected by Western blot analysis.
Statistical analysis
All of the statistical analyses were performed using SPSS
17.0 (IBM, IL, USA) software. Student’s t test, χ2 test, or
Wilcoxon’s test were used to analyze the significance of
the differences between groups. The overall survival
(OS) and disease-free survival (DFS) dates were analyzed
by the Kaplan–Meier method with the log-rank test.
Pearson correlation analyses were used to investigate the
correlation between AGAP2-AS1 and P21 (CDKN1A) or
E-cadherin expression. Two-sided P values were calcu-
lated and those less than 0.05 were considered significant.
Results
AGAP2-AS1 is upregulatd in the GC tissues and
associated with poor prognosis
To determine the expression pattern of AGAP2-AS1 in
the human GC tissues, we first analyzed its expression
in two public gene profiling datasets (GSE65801 [21]
and GSE51575 [22]) from Gene Expression Omnibus
(GEO) database. The analysis results showed that
AGAP2-AS1 was highly expressed in the human GC
tissues (Fig. 1a). Then, we examined the AGAP2-AS1
expression level in a cohort of the 50 paired GC and
nontumor tissues to validate the analysis results. Con-
sistent with these results, we also found that AGAP2-
AS1 expression was upregulated in the human GC tissue
samples (Fig. 1b). Simultaneously, we determined the ex-
pression level of AGAP2-AS1 in GC cell lines (BGC823,
SGC7901, MGC803, AGS, and MKN45) and the GES1
cells, an immortalized, normal human gastric cell line,
using qRT-PCR. Compared with the level in the GES1
cells, AGAP2-AS1 exhibited higher expression levels in
GC cell lines (Fig. 1c). Collectively, these results indicate
that AGAP2-AS1 is upregulated in GC.
The GC patients were divided into groups with high
(n = 25, fold change ≥median) and low AGAP2-AS1 ex-
pression (n = 25, fold change ≤median) to investigate the
relationship between this variable and clinicopathology
in such patients (Fig. 1d). The statistical analysis showed
that a higher AGAP2-AS1 level was associated with
larger tumors (P = 0.010), advanced pathological stage
(P = 0.001), and lymph node metastasis (P = 0.022).
Table 1 Correlation between AGAP2-AS1 expression and
clinicopathological characteristics of gastric cancer patients
(n = 50)
Characteristics AGAP2-AS1 expression P value
Low High
Age <50 9 12 0.567
>50 16 13
Gender Male 13 15 0.776
Fmale 12 10
location Distal 11 7 0.338
Middle 8 13
Proximal 6 5
Tumor size <5 cm 18 8 0.010*
>5 cm 7 17




Lymphatic metastasis NO 18 9 0.022*
YES 7 16




*Overall P < 0.05
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However, AGAP2-AS1 expression level was not re-
lated to other factors including gender (P = 0.776) and
age (P = 0.567) in GC (Table 1). Moreover, Kaplan–Meier
survival analysis revealed that patients with higher
AGAP2-AS1 levels had shorter OS and PFS than those
with lower AGAP2-AS1 levels (Fig. 1e).
SP1 activated AGAP2-AS1 expression in the GC cells
Increasing evidence has revealed that several key tran-
scription factors (TFs) and epigenetic regulators also
contribute to lncRNA dysregulation in the human
cancer cells, such as p53 [23], E2F1 [24], and EZH2 [25].
Although the above findings and a previous study have
shown that AGAP2-AS1 is overexpressed in the human
NSCLC and GC tissues, the factors involved in AGAP2-
AS1 dysregulation remained unclear. Using the online
TF prediction software JASPAR, we found that there are
several SP1 binding sites in the AGAP2-AS1 promoter
regions (Fig. 2a). Moreover, knockdown of SP1 in the
BGC823 and AGS cells by transfection with siRNA
decreased AGAP2-AS1 expression (Fig. 2b, c), while
ectopic overexpression of SP1 promoted AGAP2-AS1
expression (Fig. 2d). Furthermore, we designed three
paired primers covering the promoter regions containing
potential SP1 binding sites and performed ChIP assays
to evaluate whether SP1 could bind to these sites. The
results showed that SP1 could bind to all of these promoter
regions of AGAP2-AS1 (Fig. 2e). In addition, the promoter
region (2000 bp) of AGAP2-AS1 was inserted into a PGL3
luciferase reporter vector, and Dual-Luciferase Reporter
analysis showed that SP1 could bind to this region and ac-
tivate luciferase (Fig. 2f). These results indicated that
AGAP2-AS1 upregulation in GC may be activated partly
by SP1.
Knockdown of AGAP2-AS1 inhibits GC cell proliferation
and induced cell cycle arrest
As the BGC823 and AGS cells had relative higher
AGAP2-AS1 expression levels than that in other cell
lines, we thereby chose these two cell lines for further
investigation. To evaluate the possible biological func-
tion of AGAP2-AS1 in the GC cells, we transfected the
BGC823 and AGS cells with two different siRNAs or
shRNA vector against AGAP2-AS1, both of which could
effectively knock down AGAP2-AS1 expression. We also
overexpressed AGAP2-AS1 by transfection with an
Fig. 2 SP1 activates AGAP2-AS1 expression in GC cells. a JASPR online prediction of SP1 binding sites in the AGAP2-AS1 promoter regions. b Western
blot analysis of SP1 protein levels in the AGS and BGC823 cells after transfection with SP1 siRNA. c qRT-PCR analysis of SP1 and AGAP2-AS1 expression
in AGS and BGC823 cells after transfection with SP1 siRNA. d Western blot and qRT-PCR analyses of SP1 and AGAP2-AS1 expression in the AGS and
BGC823 cells after transfection with SP1 vector or empty vector. e ChIP-qPCR analysis of SP1 occupancy in the AGAP2-AS1 promoter regions in the
BGC823 and AGS cells. IgG was used as a negative control. f Luciferase reporter analysis of luciferase activity in the HEK293 cells cotransfected with
pGL3-AGAP2-AS1 and SP1 vector or an empty vector. *P < 0.05, **P < 0.01
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AGAP2-AS1 overexpression vector (Additional file 2:
Figure S1a). Curves of the growth in these experiments,
as detected by MTT assays, showed that AGAP2-AS1
knockdown impaired BGC823 and AGS cell growth,
while AGAP2-AS1 overexpression promoted the prolife-
ration of these cells (Fig. 3a, b). Consistent with these
MTT assay results, knockdown of AGAP2-AS1 drastic-
ally inhibited the colony formation ability of the GC
cells, while AGAP2-AS1 overexpression enhanced this
ability (Fig. 3c, d). To determine the mechanisms under-
lying the growth suppression after AGAP2-AS1 knock-
down, we assessed the effect of this on apoptosis.
However, the results of flow cytometry analysis showed
that AGAP2-AS1 downregulation had no effect on the
apoptosis of the BGC823 cells, while siRNA 2# treat-
ment increased the rate of apoptosis of the AGS cells by
about 6% (Fig. 3e).
To determine whether a change in cell cycle progression
was involved in the AGAP2-AS1-mediated regulation of
cell proliferation, we performed EdU staining assays. The
results of these assays showed that the rate of the EdU-
positive cells was reduced in AGAP2-AS1-downregulated
BGC823 and AGS cells (Fig. 4a and b). In addition,
the results of flow cytometry analysis showed that
AGAP2-AS1 downregulation increased the proportion
of G0/G1 phase cells and decreased the proportion of
S phase cells (Fig. 4c, d). These findings indicate that
AGAP2-AS1 could promote the cell cycle progression
of the GC cells.
AGAP2-AS1 promotes cell migration and invasion in GC
To further determine whether AGAP2-AS1 is associated
with the progression of GC, we analyzed its effect on the
migration and invasion of the BGC823 and AGS cells.
Using a Transwell assay, we found that the BGC823 and
AGS cell migration and invasion were significantly im-
paired after the knockdown of AGAP2-AS1 (Fig. 5a–c).
Conversely, AGAP2-AS1 overexpression in these cells
Fig. 3 The effect of AGAP2-AS1 on cell proliferation and cell cycle progression. a MTT assay analysis of the growth curves for the BGC823 and
AGS cells after transfection with AGAP2-AS1 siRNA or negative control. b MTT assay analysis of the growth curves for the BGC823 and AGS cells
after transfection with AGAP2-AS1 vector or empty vector. c, d Analysis of the colony formation ability of the BGC823 and AGS cells after transfection
with AGAP2-AS1 siRNA, vector, or negative control and empty vector. e Flow cytometry cell apoptosis assays were used to analyze the apoptosis of
the BGC823 and AGS cells 48 h after transfection with si-AGAP2-AS1. AV annexin V. The rate of apoptosis was represented by the proportion of annexin
V-positive cells. *P < 0.05, **P < 0.01
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promoted cell migration and invasion (Fig. 5d, e). Taken
together, these findings indicate that AGAP2-AS1 has
important roles in GC progression.
AGAP2-AS1 downregulation suppresses GC cell
tumorigenesis in vivo
To verify the above findings obtained in vitro, we con-
structed the BGC823 cells stably expressing sh-AGAP2-
AS1 or negative control by transfection with shRNA
vectors. We then injected the control cells and BGC823
cells with stable knockdown of AGAP2-AS1 into nude
mice to evaluate whether AGAP2-AS1 affects GC cell
tumorigenesis in vivo. The tumors formed by AGAP2-
AS1-silenced cells clearly grew much slower than those
formed by the control cells (Fig. 6a, b). Moreover, the
tumors from the AGAP2-AS1-knockdown group were
significantly lighter in weight than those in the control
group (Fig. 6c). qRT-PCR analysis of the tumor tissues
from the AGAP2-AS1-knockdown and control groups
showed that AGAP2-AS1 expression was significantly
downregulated in the former group (Fig. 6d). Further-
more, immunohistochemical analysis revealed that the
tumors formed by the AGAP2-AS1-knockdown cells ex-
hibited lower Ki-67 staining than those formed by the
control cells (Fig. 6e).
P21 and E-cadherin are targets of AGAP2-AS1 in the
GC cells
Previous studies have demonstrated that lncRNAs regu-
late underlying targets by binding to RNA-binding pro-
teins or functioning as endogenous RNAs competing for
microRNAs. To determine the molecular mechanism by
which AGAP2-AS1 regulates its targets in the GC cells,
we first examined its distribution in these cells. The re-
sults of fractionation analysis showed that most of the
AGAP2-AS1 RNA is located in the nucleus of the GC
cells (Fig. 7a), suggesting that it might regulate targets at
the transcriptional level. As such, we performed RIP
assays to determine whether there is an interaction
between AGAP2-AS1 and some well-known RNA-
binding proteins including EZH2, SUZ12, LSD1, CoREST,
and HuR. The results showed that AGAP2-AS1 could
bind to EZH2 and LSD1 in the GC cells (Fig. 7b). Con-
sistent with this, the RNA pull-down analysis also
showed that AGAP2-AS1 RNA could directly interact
with EZH2 and LSD1 in the BGC823 cells (Fig. 7c).
These results suggest that AGAP2-AS1 can epigeneti-
cally suppress underlying targets by interacting with
EZH2 and LSD1.
We also examined the expression levels of some im-
portant tumor suppressors including LATS1, LATS2,
KLF2, and PTEN; cyclin-dependent kinase inhibitors
Fig. 4 The effect of AGAP2-AS1 on cell cycle progression. a, b EdU staining assays were performed to determine the growth of the BGC823 and
AGS cells 48 h after transfection with si-AGAP2-AS1. c, d BGC823 and AGS cell cycle progression after transfection with AGAP2-AS1 siRNA or negative
control was evaluated by flow cytometry by measuring the proportions of the cells in the G0/G1, S, and G2/M phases using PI staining. All experiments
were performed in biological triplicates. *P < 0.05, **P < 0.01
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including P21, CDKN2B (P15), and CDKN2A (P16); and
cell migration and invasion regulators, including TIMP3
and E-cadherin, in the BGC823 and AGS cells after the
knockdown of AGAP2-AS1. The results of qRT-PCR
showed that the inhibition of AGAP2-AS1 increased
P21, RND1, and E-cadherin expression in the BGC823
cells, while KLF2, P21, and E-cadherin expression was
upregulated in the AGAP2-AS1-downregulated AGS
cells (Fig. 7d). Hence, we chose P21 and E-cadherin as
potential targets of AGAP2-AS1 in the GC cells for fur-
ther validation. Consistent with the results of qRT-PCR,
Western blot analysis showed that P21 and E-cadherin
protein levels were increased in the si-AGAP2-AS1-
transfected BGC823 and AGS cells (Fig. 7e). Meanwhile,
immunofluorescence staining confirmed that the expres-
sion level of E-cadherin was increased in the AGAP2-AS1-
downregulated BGC823 cells (Fig. 7f ). These findings
suggest that P21 and E-cadherin might be important
underlying targets of AGAP2-AS1 in GC.
AGAP2-AS1 epigenetically suppresses P21 and E-cadherin
expression by interacting with EZH2 and LSD1
To further determine whether AGAP2-AS1 regulates
its underlying targets by interacting with EZH2 and
LSD1, we determined P21 and E-cadherin expression
levels in the BGC823 and AGS cells transfected with
EZH2 and LSD1 siRNAs. Interestingly, knockdown of
EZH2 and LSD1 also upregulated P21 and E-cadherin
expression in the GC cells (Fig. 8a, b, and Additional
file 3: Figure S2). To confirm whether EZH2 or LSD1
could bind the promoter regions of P21 and E-
cadherin, we performed ChIP analysis. The results
showed that EZH2 and LSD1 could bind to the P21
and E-cadherin promoter regions; however, knock-
down of AGAP2-AS1 reduced this binding (Fig. 8c, d).
Finally, correlation analysis showed that AGAP2-AS1
expression was negatively correlated with P21 and E-
cadherin expression in a cohort of the 50 paired GC
tissue samples (Fig. 8e).
Fig. 5 AGAP2-AS1 promotes cell migration and invasion in GC. a–c The migratory and invasive abilities of the BGC823 and AGS cells after
transfection with AGAP2-AS1 siRNA or NC were assessed using Transwell assays. d, e The migratory and invasive abilities of the BGC823 and AGS
cells after transfection with AGAP2-AS1 vector or empty vector were evaluated using Transwell assays. *P < 0.05, **P < 0.01
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Discussion
Recently, RNA sequencing has revealed that hundreds of
lncRNAs are dysregulated in several human cancers, in-
dicating that lncRNAs are critical regulators during
tumorigenesis and cancer progression [26–28]. Among
these lncRNAs, some important ones have been well
characterized and their underlying mechanisms in the
cancer cells have been revealed. For example, the lncRNA
Ras suppressor protein 1 pseudogene 2 (RSU1P2) was
shown to be overexpressed in cervical cancer and to play
a tumor-promoting role by acting as a ceRNA for micro-
RNA let-7a and regulating the expression of IGF1R, N-
myc, and EphA4 [29]. In addition, the expression of the
lncRNA GCASPC was significantly lower in the gallblad-
der cancer (GBC) tissues, and GCASPC overexpression
was found to suppress cell proliferation by binding to
pyruvate carboxylase [30]. In the present study, we
identified that the lncRNA AGAP2-AS1 is upregulated
in the human GC tissues and cells by analyzing two in-
dependent datasets from GEO; we also validated these
findings in a cohort of 50 paired GC and nontumor tis-
sue samples. Moreover, we showed that increased
AGAP2-AS1 expression was associated with a poor
prognosis and shorter survival time in GC patients. In
vitro and in vivo assays revealed that AGAP2-AS1 si-
lencing inhibited cell proliferation, migration, and inva-
sion, while AGAP2-AS1 overexpression promoted cell
proliferation and invasion, suggesting that AGAP2-AS1
may have an oncogenic function in gastric tumorigenesis
and progression.
Although the expression of numerous lncRNAs has
been found to be dysregulated in human cancers, the
factors involved in their altered expression pattern in the
cancer cells are still not well understood. Interestingly, a
few studies have revealed that lncRNA transcription can
also be regulated by some TFs and epigenetic regulators.
Xu et al. reported that SP1 activated expression of the
lncRNA TINCR in the GC cells, resulting in the promo-
tion of cell proliferation [31]. Meanwhile, EZH2 was
shown to suppress lncRNA SPRY4-IT1 expression in the
NSCLC cells, and DNMT1-mediated DNA methylation
was found to lead to MEG3 silencing in gliomas [25, 32].
In this study, using the JASPR online TF binding predic-
tion database, we found that there are several SP1 bind-
ing sites in the promoter region of AGAP2-AS1. Then,
by applying ChIP and luciferase reporter assays, we de-
termined that SP1 could bind to the AGAP2-AS1 pro-
moter region and activate its transcription. Our findings
combined with previous studies suggest that the abnor-
mal activation of transcription factors may play an im-
portant role in lncRNA overexpression in the human
cancer cells.
Generally, lncRNAs participate in the regulation of
cancer cell phenotype by suppressing the expression
of tumor suppressors or activating oncogene tran-
scription via diverse mechanisms, such as chromatin
Fig. 6 AGAP2-AS1 knockdown inhibits GC cell tumor growth in vivo. a The BGC823 cells with stable knockdown of AGAP2-AS1 were used for the
in vivo tumorigenesis assays. The tumors formed from the BGC823 cells with AGAP2-AS1 knockdown and the control cells in nude mice are
shown. b The tumor growth curves were measured 3 days after the injection of the BGC823 cells once the tumor had formed, and the volume
was calculated every 3 days. c Tumor weights in the sh-AGAP2-AS1 and control groups are presented. d qRT-PCR analysis of AGAP2-AS1 expression
levels in the tumor tissues formed from the AGAP2-AS1-downregulated cells or control cells. e Tumors formed from sh-AGAP2-AS1-transfected BGC823
cells showed lower Ki67-positive signals than tumors formed from the control cells. Upper; hematoxylin & eosin staining, Lower Ki67 immunostaining.
*P < 0.05, **P < 0.01
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remodeling, interacting with histone modification en-
zymes, and mediating epigenetic alteration, RNA decay,
and acting as ceRNAs for specific miRNAs [33–36]. In
this study, we performed RIP assays to determine the
RNA-binding proteins with which AGAP2-AS1 interacts
and found that AGAP2-AS1 could bind to EZH2 and
LSD1 in the GC cells. Interestingly, the well-known
lncRNA HOTAIR also could interact with EHZ2 and
LSD1, which has similar function and is similarly located
in the same chromosome as AGAP2-AS1 [37]. Further,
qRT-PCR analysis revealed that P21 and E-cadherin might
be novel targets of AGAP2-AS1 in the GC cells, and ChIP
assays revealed that EZH2 and LSD1 could bind to their
promoter regions. Importantly, the knockdown of
AGAP2-AS1 reduced the levels of interaction of EZH2
and LSD1 with the P21 and E-cadherin promoters.
P21 is a key member of the cyclin-dependent kinase
inhibitor family, which controls cell cycle progression.
Loss of P21 expression could lead to uncontrolled cell
proliferation and the development of cancer, and epi-
genetic modifications have been found to be involved
in decreased P21 expression in the cancer cells
[38, 39]. The loss of E-cadherin expression is a
hallmark of epithelial–mesenchymal transition, which
is implicated in the promotion of cancer cell migra-
tion and metastasis [40, 41]. Recent studies have re-
vealed that the epithelial–mesenchymal transition is a
potential mechanism by which the cancer cells detach
from primary tumors [41]. Therefore, AGAP2-AS1-
mediated suppression of P21 and E-cadherin could
account for its promotion of cell proliferation, migra-
tion, and invasion in GC.
Fig. 7 AGAP2-AS1 interacting with EZH2 and LSD1 in the GC cells. a The distribution of AGAP2-AS1 levels in the cytoplasmic or nuclear fraction
of GC cell lines was determined by qRT-PCR. U1 was used as a nuclear control; GAPDH was used as a cytoplasmic control. b The AGAP2-AS1 RNA
levels in EZH2, LSD1, SUZ12, CoREST, and HuR immunoprecipitates were determined by qRT-PCR, and data are presented as fold enrichment relative
to IgG immunoprecipitates. c EZH2 and LSD1 protein levels in immunoprecipitates with AGAP2-AS1 RNA were determined by Western blot. HuR
protein immunoprecipitates with AR RNA were used as a positive control. d qRT-PCR analysis of the expression levels of KLF2, LATS1, and LATS2, and
others in the BGC823 and AGS cells after transfection with AGAP2-AS1 or negative control siRNAs. e Western blot analysis of the protein levels of P21
and E-cadherin in the BGC823 and AGS cells after transfection with AGAP2-AS1 or negative control siRNAs. f Immunofluorescence staining analysis of
E-cadherin in BGC823 cells after transfection with AGAP2-AS1 or negative control siRNAs. *P < 0.05, **P < 0.01
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Conclusions
Taking the obtained findings together, our study
shows for the first time that expression of the
lncRNA AGAP2-AS1 is upregulated in the GC tissues
and cells, and increased AGAP2-AS1 is associated
with poor prognosis of GC patients. Knockdown of
AGAP2-AS1 exerted tumor-suppressive effects by in-
hibiting cell proliferation, migration, and invasion.
Furthermore, the transcription factor SP1 activated
AGAP2-AS1 transcription, and AGAP2-AS1-mediated
oncogenic effects occurred partially through epigene-
tic suppression of P21 and E-cadherin expression by
binding to EZH2 and LSD1. Our findings increase
our understanding of the pathogenesis and progres-
sion of GC and may facilitate the development of
lncRNA-directed diagnostics and therapeutics in GC.
However, whether AGAP2-AS1 can regulate other
targets through different mechanisms was not inves-
tigated, so this should be focused on in further
studies.
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Additional file 1: Table S1. Primers, siRNAs and shRNAs sequence.
(XLSX 13 kb)
Additional file 2: Figure S1. Modulation of AGAP2-AS1 expression in
the BGC832 and AGS cells. (a) qRT-PCR analysis of AGAP2-AS1 expression
levels in the BGC823 and AGS cells after transfection with AGAP2-AS1 or
negative control siRNAs. (b) qRT-PCR analysis of AGAP2-AS1 expression
levels in the BGC823 and AGS cells after transfection with sh-AGAP2-AS1
vector or empty vector. (c) qRT-PCR analysis of AGAP2-AS1 expression
levels in the BGC823 and AGS cells after transfection with AGAP2-AS1
vector or empty vector. *P < 0.05, **P < 0.01. (TIF 1489 kb)
Additional file 3: Figure S2. Knockdown of EZH2 and LSD1 expression
in the BGC823 and AGS cells. (a, b) Western blot analysis of the
expression levels of EZH2 in the BGC823 and AGS cells after transfection
with EZH2 or negative control siRNAs. (c, d) Western blot analysis of the
expression levels of LSD1 in BGC823 and AGS cells after transfection with
LSD1 or negative control siRNAs. *P < 0.05, **P < 0.01. (TIF 1553 kb)
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Fig. 8 AGAP2-AS1 epigenetically suppresses P21 and E-cadherin by interacting with EZH2 and LSD1. a, b qRT-PCR analysis of the expression levels
of P21 and E-cadherin in the BGC823 and AGS cells after transfection with EZH2, LSD1, or negative control siRNAs. c, d ChIP-qPCR analysis of EZH2,
H3K27me3, LSD1, and H3K4me2 occupancy in the P21 and E-cadherin promoters in the BGC823 and AGS cells after transfection with AGAP2-AS1 or
NC siRNA. IgG was used as a negative control. e The relationship between AGAP2-AS1 expression and P21/E-cadherin in the GC tissues was analyzed.
*P < 0.05, **P < 0.01
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